Our Factsheet
Check out Myllia's technology platform enabling drug target discovery and functional genomics at single-cell resolution
Myllia Biotechnology is redefining functional genomics by uniting CRISPR-based perturbations, single-cell resolution, and advanced computational modeling. Our platform integrates high-content CRISPR screens with single-cell RNA sequencing in primary human cells to deliver deeply physiologic, mechanistic insights.
By generating large-scale, custom perturbation datasets, we enable AI-driven foundation models of virtual cells that infer causal relationships, reveal mechanisms of action, and accelerate unbiased target discovery. This end-to-end approach produces genetically validated, high-value targets for early-stage drug development and generates AI-ready data at a scale and fidelity previously impossible.
In essence, Myllia delivers causal, mechanism-resolved target discovery in disease-relevant human cells – going beyond atlases to produce actionable drug hypotheses.
Download Myllia’s factsheet here: